Table 8.

Evaluation of tapentadol PR treatment by the treating physicians at the end of observation (proportion of patients with “good” or “very good” ratings).

	Patients aged >65 years (n = 752)	Patients aged ≤65 years (n = 282)
Analgesia	76.4% (n = 698)	85.2% (n = 270)
General tolerability	84.9% (n = 697)	89.7% (n = 272)
Gastrointestinal tolerability	85.9% (n = 695)	88.5% (n = 269)
CNS tolerability	86.5% (n = 691)	91.5% (n = 271)
Balance between efficacy and tolerability	82.5% (n = 690)	89.5% (n = 267)
Quality of life	70.8% (n = 694)	81.7% (n = 268)
Compliance	86.9% (n = 694)	89.5% (n = 266)
Overall treatment success	78.9% (n = 693)	85.6% (n = 270)

n = number of patients with valid data. CNS, central nervous system. PR, prolonged release.